Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.47 |
| ▸ | TUBB | P07437 | 3/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29217294 | 0.84 | TDO2 (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22118422 | 0.84 | TDO2 (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22747626 | 0.77 | TACR1 (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22747530 | 0.76 | KDM4E (0.47) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22161378 | 0.75 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29033496 | 0.74 | MTNR1A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22747549 | 0.74 | MTNR1A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30613284 | 0.73 | NPC1 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6851358 | 0.72 | CA12 (0.56) | MEN1MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL22118353 | 0.71 | MEN1 (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-02-06 | — | — | US | disclosed |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| CN-113453760-B | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| CN-113453760-A | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | TUBB4A 1985/4885TUBB 1918/4885TUBA3C 3462/4885 |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, SAAL1 | TUBB4A 1985/4885TUBB 1918/4885TUBA3C 3462/4885 |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | TUBB4A 1985/4885TUBB 1918/4885TUBA3C 3462/4885 |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | TUBB4A 2620/4885TUBB 2699/4885TUBA3C 3500/4885 |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, SAAL1, LOXL1 | TUBB4A 2179/4885TUBB 1602/4885TUBA3C 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.